Furthermore, the patients with advanced NSCLC (mainly the never smokers, patients receiving second-line treatment or intercalated therapy and Asian-dominant groups) would benefit from EGFR-TKI combination therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.